The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
- PMID: 36587473
- DOI: 10.1016/j.ctrv.2022.102500
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
Abstract
A novel class of drugs, antibody-drug conjugates (ADCs), are now rapidly emerging as highly effective treatments for solid tumours. ADCs conjugate conventional chemotherapeutics with highly selective targeted monoclonal antibodies. Anti-HER2 therapies selectively target cancer cells expressing human epidermal growth factor receptor 2 (HER2), among them trastuzumab has been the first HER2-targeting monoclonal antibody to achieve successful results that made it the backbone of anti-HER2 therapies. Trastuzumab drug conjugates (T-DCs), use trastuzumab as a selective antibody to lead cytotoxic drugs inside cancer cells. Trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-Dxd) are the two approved T-DCs. T-Dxd along with other five T-DCs represents "second generation ADCs" that has been firstly tested in HER2 positive breast cancer (BC) and then in HER2-low BC and other cancers showing promising results thanks to extraordinary and innovative pharmacokinetic and pharmacodynamic characteristics. The evidence generated so far are establishing them as a completely new class of agents effective in solid cancer treatments but also warrants physicians against unconventional toxicity profiles. The role of T-DCs in HER2-positive BC has been largely reviewed, while in this review, we provided for the first time in literature an overview of trastuzumab drug conjugates (T-DCs) approved and/or in clinical development with a specific focus on their efficacy and safety profile in HER2-low BC and other solid tumours different from BC. We started by analysing T-DCs biological characteristics that underly the differences in T-DCs pharmacodynamics and safety profile, then presented the main evidence on the activity and efficacy of these emerging T-DCs in HER2-low BC and other HER2 overexpressing and/or mutated solid tumours and lastly, we provided an overview of the complex and still evolving scenario in which these compounds should be allocated. A specific focus on possible combination strategies with other drugs such as immunotherapy, chemotherapy and target therapy, to increase T-DCs activity and eventually overcome future upcoming resistance mechanisms, are here also critically reviewed.
Keywords: ADCs; Colon-rectal cancer; Gastric cancer; HER2-low breast cancer; Non-small-cell lung cancer; Trastuzumab.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.Clin Exp Metastasis. 2024 Apr;41(2):91-102. doi: 10.1007/s10585-024-10278-2. Epub 2024 Feb 17. Clin Exp Metastasis. 2024. PMID: 38367127 Free PMC article.
-
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure.ESMO Open. 2023 Aug;8(4):101608. doi: 10.1016/j.esmoop.2023.101608. Epub 2023 Jul 17. ESMO Open. 2023. PMID: 37467660 Free PMC article. Review.
-
Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.Oncologist. 2023 Oct 3;28(10):e859-e866. doi: 10.1093/oncolo/oyad127. Oncologist. 2023. PMID: 37218076 Free PMC article.
-
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.Breast Cancer Res. 2021 Aug 11;23(1):84. doi: 10.1186/s13058-021-01459-y. Breast Cancer Res. 2021. PMID: 34380530 Free PMC article. Review.
-
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6. Eur J Med Chem. 2019. PMID: 31563805 Review.
Cited by
-
Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.Front Pharmacol. 2024 Jan 30;14:1332539. doi: 10.3389/fphar.2023.1332539. eCollection 2023. Front Pharmacol. 2024. PMID: 38352694 Free PMC article. Review.
-
A Comprehensive Review on the State of the Art of Breast Cancers in Italy.Curr Med Chem. 2024;31(18):2486-2506. doi: 10.2174/0109298673283289231214095230. Curr Med Chem. 2024. PMID: 38213176 Review.
-
Nanomaterials augmented bioeffects of ultrasound in cancer immunotherapy.Mater Today Bio. 2023 Dec 22;24:100926. doi: 10.1016/j.mtbio.2023.100926. eCollection 2024 Feb. Mater Today Bio. 2023. PMID: 38179429 Free PMC article. Review.
-
Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report.Case Rep Oncol. 2023 Nov 21;16(1):1425-1435. doi: 10.1159/000534572. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 38028580 Free PMC article.
-
The Emerging Roles of Exosomal miRNAs in Breast Cancer Progression and Potential Clinical Applications.Breast Cancer (Dove Med Press). 2023 Nov 16;15:825-840. doi: 10.2147/BCTT.S432750. eCollection 2023. Breast Cancer (Dove Med Press). 2023. PMID: 38020052 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous